How Some Manufacturers Are Navigating COVID-19 Pharma Supply Chain Challenges
Gilead, Vetter, Lonza and academic experts share what they’re focusing on to keep producing drugs during the pandemic.
You may also be interested in...
Experts describe the agile, localized supply chains that will emerge, only perhaps to be forgotten just-in-time for the next crisis.
Responses to US FDA draft guidance suggest more promptness while also more elaborate processes for agency decision making based on remote methods. Questions include what’s voluntary, what’s mandatory, what can be decided remotely, and how to remotely move on from warning letters.
Memo outlines how US agency ensured sufficient delivery of updated COVID-19 vaccine doses even as it navigated unresolved inspection findings of the Catalent plant where the additional doses had been manufactured.